Waters Corporation $WAT Shares Sold by Hikari Tsushin Inc.

Posted by George Bondi on Jun 12th, 2026

Hikari Tsushin Inc. reduced its stake in shares of Waters Corporation (NYSE:WAT – Free Report) by 10.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 20,556 shares of the medical instruments supplier’s stock after selling 2,441 shares during the period. Waters makes up 0.5% of Hikari Tsushin Inc.’s holdings, making the stock its 19th biggest holding. Hikari Tsushin Inc.’s holdings in Waters were worth $7,808,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Mondrian Investment Partners LTD purchased a new position in shares of Waters in the third quarter valued at $1,397,000. SG Americas Securities LLC increased its stake in Waters by 543.8% during the 4th quarter. SG Americas Securities LLC now owns 37,244 shares of the medical instruments supplier’s stock worth $14,146,000 after buying an additional 31,459 shares during the period. Mackenzie Financial Corp lifted its holdings in Waters by 12.2% in the 3rd quarter. Mackenzie Financial Corp now owns 231,852 shares of the medical instruments supplier’s stock worth $69,512,000 after buying an additional 25,182 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Waters by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 7,656,891 shares of the medical instruments supplier’s stock worth $2,295,612,000 after buying an additional 246,128 shares in the last quarter. Finally, Alberta Investment Management Corp purchased a new position in Waters in the 3rd quarter valued at about $4,677,000. 94.01% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Wei Jiang bought 500 shares of Waters stock in a transaction on Monday, March 16th. The shares were bought at an average price of $289.46 per share, with a total value of $144,730.00. Following the acquisition, the director directly owned 3,441 shares in the company, valued at approximately $996,031.86. This represents a 17.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.31% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on WAT shares. The Goldman Sachs Group upgraded Waters to a “strong-buy” rating in a research note on Wednesday, April 1st. UBS Group increased their price target on Waters from $330.00 to $375.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th. TD Cowen raised their price objective on Waters from $345.00 to $385.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. Weiss Ratings restated a “hold (c)” rating on shares of Waters in a report on Monday, April 20th. Finally, Morgan Stanley cut their target price on Waters from $423.00 to $350.00 and set an “equal weight” rating on the stock in a research report on Sunday, February 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $394.56.

View Our Latest Research Report on WAT

Waters Price Performance

WAT opened at $359.80 on Friday. The company has a market capitalization of $35.33 billion, a P/E ratio of 45.72, a PEG ratio of 2.20 and a beta of 1.21. The company has a 50-day moving average of $336.59 and a 200-day moving average of $350.23. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.13 and a current ratio of 1.79. Waters Corporation has a 1-year low of $275.05 and a 1-year high of $414.15.

Waters (NYSE:WAT – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping the consensus estimate of $2.31 by $0.39. The business had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Waters had a net margin of 11.91% and a return on equity of 15.60%. The company’s quarterly revenue was up 91.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.25 earnings per share. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Equities analysts expect that Waters Corporation will post 14.5 EPS for the current fiscal year.

Waters Profile

(Free Report)

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

Waters Corporation $WAT Shares Sold by Hikari Tsushin Inc.

Insider Buying and Selling

Analyst Upgrades and Downgrades

Waters Price Performance

Waters Profile

Further Reading

You might be interested in: